摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-Methoxyphenyl)-1,4-butandion | 116332-66-2

中文名称
——
中文别名
——
英文名称
1-(2-Methoxyphenyl)-1,4-butandion
英文别名
4-(2-Methoxyphenyl)-4-oxobutanal
1-(2-Methoxyphenyl)-1,4-butandion化学式
CAS
116332-66-2
化学式
C11H12O3
mdl
——
分子量
192.214
InChiKey
BYEYMLIACLAICQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    327.2±22.0 °C(predicted)
  • 密度:
    1.096±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    14
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    43.4
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of 1,4-ketoaldehydes and 1,4-diketones by Mo-catalyzed oxidative cleavage of cyclobutane-1,2-diols
    作者:Sara Gómez-Gil、Rubén Rubio-Presa、Raquel Hernández-Ruiz、Samuel Suárez-Pantiga、María R. Pedrosa、Roberto Sanz
    DOI:10.1039/d3ob00436h
    日期:——
    A new two-step procedure for the synthesis of 1,4-dicarbonyls has been developed involving an efficient and clean Mo-catalyzed oxidative cleavage of cyclobutane-1,2-diols with DMSO, which is used as solvent and oxidant. The required starting glycols were prepared by nucleophilic additions of organolithiums and Grignard reagents to easily available 2-hydroxycyclobutanones.
    已经开发了一种用于合成 1,4-二羰基化合物的新两步法,涉及使用用作溶剂和氧化剂的 DMSO环丁烷-1,2-二醇进行有效且清洁的 Mo 催化氧化裂解。所需的起始乙二醇是通过有机锂格氏试剂对容易获得的 2-羟基环丁酮进行亲核加成而制备的。
  • LAATSCH, HARTMUT;PUDLEINER, HEINZ, LIEBIGS ANN. CHEM.,(1989) N, C. 863-881
    作者:LAATSCH, HARTMUT、PUDLEINER, HEINZ
    DOI:——
    日期:——
  • KRUSE, CH. G.;BOUV, J. P.;VAN, RES R.;VAN, DE KUILEN A.;DEN, HARTOG A. J., HETEROCYCLES, 26,(1987) N 12, 3141-3151
    作者:KRUSE, CH. G.、BOUV, J. P.、VAN, RES R.、VAN, DE KUILEN A.、DEN, HARTOG A. J.
    DOI:——
    日期:——
  • 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
    申请人:Genzyme Corporation
    公开号:US20180093981A1
    公开(公告)日:2018-04-05
    A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
  • US9744153B2
    申请人:——
    公开号:US9744153B2
    公开(公告)日:2017-08-29
查看更多